- Home
- AIRI vs SPRB Comparison
AIRI vs SPRB Comparison
Compare AIRI & SPRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRI
- SPRB
- Stock Information
- Founded
- AIRI 1979
- SPRB 2014
- Country
- AIRI United States
- SPRB United States
- Employees
- AIRI N/A
- SPRB N/A
- Industry
- AIRI Military/Government/Technical
- SPRB Medicinal Chemicals and Botanical Products
- Sector
- AIRI Industrials
- SPRB Health Care
- Exchange
- AIRI Nasdaq
- SPRB Nasdaq
- Market Cap
- AIRI 15.0M
- SPRB 15.7M
- IPO Year
- AIRI N/A
- SPRB 2020
- Fundamental
- Price
- AIRI $3.90
- SPRB $0.42
- Analyst Decision
- AIRI
- SPRB Hold
- Analyst Count
- AIRI 0
- SPRB 7
- Target Price
- AIRI N/A
- SPRB $2.17
- AVG Volume (30 Days)
- AIRI 27.9K
- SPRB 417.1K
- Earning Date
- AIRI 03-31-2025
- SPRB 03-12-2025
- Dividend Yield
- AIRI N/A
- SPRB N/A
- EPS Growth
- AIRI N/A
- SPRB N/A
- EPS
- AIRI N/A
- SPRB N/A
- Revenue
- AIRI $53,657,000.00
- SPRB $7,101,000.00
- Revenue This Year
- AIRI $7.29
- SPRB N/A
- Revenue Next Year
- AIRI $1.50
- SPRB N/A
- P/E Ratio
- AIRI N/A
- SPRB N/A
- Revenue Growth
- AIRI 3.31
- SPRB N/A
- 52 Week Low
- AIRI $3.03
- SPRB $0.34
- 52 Week High
- AIRI $9.44
- SPRB $5.95
- Technical
- Relative Strength Index (RSI)
- AIRI 28.76
- SPRB 58.94
- Support Level
- AIRI $4.19
- SPRB $0.38
- Resistance Level
- AIRI $4.25
- SPRB $0.42
- Average True Range (ATR)
- AIRI 0.11
- SPRB 0.03
- MACD
- AIRI -0.03
- SPRB 0.00
- Stochastic Oscillator
- AIRI 23.81
- SPRB 69.77
About AIRI Air Industries Group
Air Industries Group is an aerospace and defense company. Its manufactures and designs structural parts and assemblies that focus on flight safety, including landing gear, arresting gear, engine mounts, flight controls, throttle quadrants, jet engines, and other components. The company also provides sheet metal fabrication of aerostructures, tube bending, and welding services.
About SPRB Spruce Biosciences Inc.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).